Cantor Fitzgerald resumed coverage on Cidara Therapeutics
$CDTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $41.00 | Buy | H.C. Wainwright |
| 3/12/2025 | $46.00 | Mkt Outperform | Citizens JMP |
| 1/27/2025 | Overweight | Cantor Fitzgerald | |
| 12/13/2024 | $34.00 | Outperform | RBC Capital Mkts |
| 11/8/2024 | $33.00 | Buy | Guggenheim |
| 8/14/2024 | $24.00 | Neutral → Buy | H.C. Wainwright |
| 12/3/2021 | $6.00 | Buy | H.C. Wainwright |
| 9/22/2021 | $9.00 → $8.00 | Buy | Aegis Capital |
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
SCHEDULE 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)